-
The Role of Mycobacterium leprae Phenolic
Glycolipid I (PGL-I) in Serodiagnosis and in
the Pathogenesis of Leprosy
JOHN S. SPENCER & PATRICK J. BRENNAN
Department of Microbiology, Immunology & Pathology,
Colorado
State University, Fort Collins, CO 80523-1682, USA
Accepted for publication 21 September 2011
Summary PGL-I (phenolic glycolipid I) emerged in the early 1980s
on the one hand
as part of intensive efforts to dene the typing antigens of a
host of Mycobacterium
spp. and also from characterisation of the lipids of skin
biopsies from highly bacillary
positive lepromatous leprosy patients. PGL-I, despite its
extreme lipophilicity due to
its inherent phthiocerol dimycocerosyl component, is highly
antigenic evoking high
titre IgM antibodies in lepromatous leprosy patients,
attributable largely to the unique
3,6-di-O-methyl-b-D-glucosyl entity at the non-reducing terminus
of its trisacchar-
ide. PGL-I itself or in the form of semisynthetic
neoglycoproteins containing the
synthetic terminal disaccharide or the whole trisaccharide
chemically conjugated to
such as bovine or human serum albumin, has found its greatest
utility in the serolo-
gical diagnosis, conrmation and management of lepromatous
leprosy. PGL-I has
also been implicated in the tropism of M. leprae for Schwann
cells, through specic
binding to laminin, and to play an important role in
downregulation of the inam-
matory immune response and inhibition of dendritic cell
maturation and activation,
thereby facilitating the persistence of M. leprae/leprosy.
Introduction
Among the most signicant achievements in leprosy research over
the past 50 years was
the discovery in the early 1970s that Mycobacterium leprae could
be grown to high
numbers in a living mammalian host, the nine-banded armadillo,
Dasypus novemcinctus.
1
This development allowed for the rst time a reliable source of
bacilli which could then be
used for lipidomic, proteomic, genomic, and metabolomic studies
that eventually resulted in
major advances in understanding the basic biology of this human
pathogen. The discovery of
a phenolic glycolipid (PGL-I) specic for M. leprae was rst
reported in 1980,
2
with
subsequent reports that it was highly antigenic and capable of
inducing high antibody titers
against the unique sugar epitopes of this molecule.
36
The history of how native PGL-I
Correspondence to: John S. Spencer (e-mail:
[email protected]) or Patrick J. Brennan (e-mail:
patrick.
[email protected])
Lepr Rev (2011) 82, 344357
344 0305-7518/11/064053+14 $1.00 q Lepra
-
was rst discovered, puried, chemically characterised, the sugar
epitopes identied and
chemically synthesised and used as neoglycoproteins for the
serodiagnosis of leprosy, and the
importance of PGL-I in aspects of the pathogenesis of leprosy,
is now told.
DISCOVERY OF M. LEPRAE PGL- I
The recognition of an M. leprae-specic antigen, a glycolipid,
came from two separate
approaches. Brennan and colleagues in the late 1970s/early 1980s
had reported considerable
success in dening the surface/cell wall species and
serovar/serotype-specic antigens of
a host of atypical/non-tuberculous mycobacteria (NTM), notably
members of the, then
named, Mycobacterium avium/M. intracellulare/M. scrofulaceum
(MAIS) complex, and
many others such as M. kansasii, M. szulgai, M. malmoense, M.
gordonae, M. fortutium,
M. smegmatis, etc.
7
These were invariably members of but two precise chemical
structural
entities: the so-called glycopeptidolipid (GPL) class, very
characteristic of members of the
M. avium complex;
79
and the lipooligosaccharide (LOS) grouping, such as in M.
kansasii,
M. malmoense, M. smegmatis, etc.
10
An additional class of glycolipids, the phenolic
glycolipids (PGLs), had been previously or subsequently
recognised in M. bovis,
11
M. tuberculosis smooth morphology (e.g. M. tuberculosis strain
Canetti),
12,13
but also in
such asM. kansasii
14
(in conjunction with theM. kansasii specic LOS (for a review,
see [7]).
On the heels of the discovery that M. leprae could readily
replicate in the armadillo
1
and
thereby generate a plentiful supply of the bacterium, the
National Institute of Allergy and
Infectious Diseases (NIAID) of the NIH in 1978 issued an RFP
(request for proposals) to
identify, characterise and provide to the research community, M.
leprae-specic antigens.
Two contracts were awarded, one to National Jewish Hospital in
Denver, CO (the Principal
Investigator, Patrick J. Brennan) based on the hypothesis thatM.
leprae, as for the majority of
mycobacteria, is endowed with its own particular glycolipid, and
like the majority of them,
such as those of the M. avium complex, should be highly
antigenic and thus suitable for the
specic serodiagnosis of leprosy. A second contract was awarded
to Pacic Medical Center
in Seattle, WA (the Principal Investigator, Thomas M. Buchanan),
to pursue the identication
of M. leprae specic proteins.
15
Subsequently only one contract was awarded, to Colorado
State University (Brennan had moved there in 1980); indeed this
contract was renewed
through many funding cycles until 2010 allowing a thorough
exposition of the value of PGL-I
in various aspects of the disease of leprosy, particularly
serodiagnosis.
Brennan and Barrow in 1980
2
rst reported evidence of a major glycolipid associated
with armadillo derived M. leprae, prepared according to the
Draper 1979 gentle method.
16
Lyophilised M. leprae pooled from processed M. leprae infected
armadillo livers was
extracted with acetone which favours removal of apolar lipids,
followed by CHCl
3
-CH
3
OH to
extract residual soluble lipids. Column chromatography followed
by serology using a version
of the classical Ouchterlony agar gel immunodiffusion
technique
17
demonstrated the
presence of reactive lipid(s) in some of the early eluates off
the column, reactive only with
antiserum from a lepromatous leprosy patient and an
experimentally infected armadillo,
which did not extend to serum from patients with tuberculosis or
an M. avium infection.
Secondly, it was established that the lipid was alkali stable
and on acid hydrolysis yielded two
major sugars, tentatively identied by comparative gas
chromatography (GC) as the alditol
acetates of the 6-deoxyhexoses, 3,4-di-O-methylrhamnose and
2,3-di-O-methylfucose. Both
designations (and the designation of a third minor sugar as
6-deoxytalose) proved to be wrong
and taught us a lesson in the fallacy of assigning sugar
identity based only on comparative
Mycobacterium leprae Phenolic Glycolipid I 345
-
GC retention times. However, these authors cautiously warned: At
this time we can merely
state that there is indirect evidence implicating
6-deoxyhexose-containing lipids with this
serological activity. A further prescient note was made:
Currently we are looking for
this lipid antigen in liver fractions left afterM. leprae have
been removed. The logic here is
that if cold acetone will solubilize the antigen, then much of
it may have been lost during the
fractionation steps involved in the isolation ofM. leprae.
Indeed, the prototypic procedure
18
for the isolation of both M. leprae and PGL-I from M. leprae
infected armadillo livers
and spleens, still being applied, concludes: The pellet is used
as a source of M. leprae.
The supernatant is lyophilized and weighed and used as a source
of glycolipid.
Some of the early work of Douglas B. Young was also crucial in
the discovery of PGL-I.
Upon completion of his D.Phil. at Oxford University, Dr. Young
spent his initial postdoctoral
period at The Foundation for Medical Research, Worli, Bombay,
and in 1981 published a key
study of mycobacterial lipids in skin biopsies from leprosy
patients.
19
A relatively apolar
glycolipid (called I) was identied in skin samples from high
bacillary index (BI, a measure
of the number of acid fast bacilli found in the dermis, usually
the average from up to six
biopsy sites, based on a logarithmic scale from 0 at the polar
tuberculoid end to 6 at the
polar lepromatous side of the clinical leprosy spectrum)
lepromatous leprosy patients, absent
from normal skin samples and a collection of cultivable
mycobacteria, but present in
armadillo-derived puried M. leprae. A sample of the M. leprae
glycolipid I did contain
6-deoxyhexoses according to the classical Dische &
Shettles
20
colorimetric assay. Glycolipid
I of Young
19
proved to be PGL-I as shown by the subsequent isolation and full
charac-
terisation of PGL-I from human lepromatous nodules
21
and formalin-xed human
lepromatous liver.
22
CHEMICAL STRUCTURES OF NATIVE M. LEPRAE PGL- I , - I I , - I I I
AND THE RELATED
DIM/PDIM
PGL-I occurs on the cell surface of M. leprae in copious
amounts, representing up to 3%
of the total weight of the leprosy bacillus;
23
much of the PGL-I is loosely associated
with the bacillus and is sloughed off in the homogenate during
processing. It is readily
extracted from the lyophilised infected armadillo liver or
spleen homogenates from which
M. leprae whole cells had previously been puried. Hunter et
al.
18
described in considerable
detail a protocol for the partial purication of PGL-I from this
source and three alternatives
to its full purication. The present-day protocol, responsible
for the pure PGL-I prepared
at Colorado State University and currently provided to the
Biodefense and Emerging
Infections Research Resources Repository (BEI Resources,
http://www.beiresources.org/
TBVTRMResearchMaterials/tabid/1431/Default.aspx) for
distribution to leprosy researchers
worldwide, adheres closely to this protocol. Typically, yields
of 22mg of pure PGL-I per g of
lyophilised residual tissue, which had also provided 9 10
10
acid-fastM. leprae per g, were
obtained. Armadillo liver and spleens with lower M. leprae
titers do produce workable
quantities of PGL-I, but are heavily contaminated by host
lipids, notably cholesterol. PGL-I is
very stable; 10 year old puried dried material stored at room
temperature in the dark shows
no detectable degradation and no loss of serological reactivity
in ELISA.
Obviously with such plentiful supplies of pure PGL-I available
in the mid-1980s, full
structural elucidation was readily accomplished. Indeed, Brennan
and Barrow
2
and Young
19
on the basis of elution prole and absence of amino acids
(excluding C-mycosides/GPLs)
had concluded that the specic lipid of M. leprae may be
mycosides of the A, B or G
J. S. Spencer and P. J. Brennan346
-
variety, or may be related to the glycolipid mycosides A and B
from M. kansasii and
M. bovis (referring to mycobacterial lipids based on phthiocerol
and known by their classical
names), which speculations proved to be correct.
Hunter and Brennan in 1981
3
rst corrected earlier false
2
impressions on the sugar
composition of PGL-I. They established that it had an inherent
trisaccharide composed of
3-O-methyl-rhamnose, 2,3-di-O-methyl-rhamnose and
3,6-di-O-methyl-glucose glycosidi-
cally linked to a phenol substituent; the latter sugar, dominant
epitope of the trisaccharide
entity of PGL-I, was never before found in nature. The full
structure of PGL-I was reported
in 1982 by Hunter et al.
24
: partial acid hydrolysis, permethylation,
1
H NMR and
13
C NMR
established the sequence:
3,6-di-O-Me-Glcp(b1! 4)2,3-di-O-Me-Rhap(a1! 2)3-O-Me-Rhap(a1!
phenol)
Acid hydrolysis of deacylated PGL-I yielded a phenolic
phthiocerol and mass spectro-
metry (MS) and proton NMR of the permethylated compound
demonstrated the structure:
OCH
3
|
HO-Phenyl-CH
2
-(CH
2
)
17
-CH-CH
2
-CH-(CH
2
)
4
-CH-CH-CH
2
-CH
3
|||
OH OH CH
3
Combined gas chromatography-mass spectrometry (GC-MS) showed
three tetra-methyl
branched mycocerosic acids, C
30
, C
32
, and C
34
alternatively esteried to the two hydroxyl
functions of the branched phthiocerol chain. Thus, the complete
elucidated structure of PGL-I
was shown to be:
29-{4-[O-(3,6,-di-O-methyl-b-D-glucopyranosyl)-(1 !
4)-O-(2,3-di-O-methyl-a-
L-rhamnopyranosyl)-(1 !
2)-3-O-methyl-a-L-rhamnopyranosyloxy]phenyl}-3-methoxy-
4-methyl-9,11-non-acosanediol 9,11-dimycocerosate (Figure
1).
Subsequently, Hunter and Brennan
25
discovered two other minor phenolic glycolipids,
apparent autolytic products of PGL-I, one of which, PGL-III, was
chemically dened; it
simply lacked the 3-O-methyl substituent of the terminal
3,6-di-O-methyl-glucose of PGL-I.
An important outcome of this study
25
was the denition of the phthiocerol dimycerosate
(known as both DIM and PDIM, dimycocerosyl
phthiocerol/phthioceryl dimycocerosate) of
M. leprae as consisting of a mixture of two phthiocerol
homologues, 3-methoxyl-4-methyl-
9,11-dihydroxyoctacosane and
3-methoxyl-4-methyl-9,11-dihydroxytriacontane
OCH
3
|
CH
3
-(CH
2
)
n
-CH-CH
2
-CH-(CH
2
)
4
-CH-CH-CH
2
CH
3
| | |
OH OH
CH
3
n 16 or 18 and the hydroxyl functions are acylated by a mixture
of three mycocerosic
acids, 2,4,6,8-tetramethylhexacosanoate,
2,4,6,8-tetramethyloctacosanoate and 2,4,6,8-tetra-
methyltriacontanoate. These largely extracellular phthiocerol
containing lipids exist in
amounts well in excess of the bacterial mass, estimated at more
than 138mg in 1 g of liver,
wet weight, containing 37 10
10
M. leprae bacilli. The implications for the biology of
Mycobacterium leprae Phenolic Glycolipid I 347
-
leprosy of a bacillus within a copious environment of exotic
lipids of its own making has
never been thoroughly explored.
IDENTIFYING THE IMMUNOLOGIC EPITOPE OF PGL- I
Polyclonal rabbit antisera raised against M. leprae whole cells
and pooled sera from
lepromatous leprosy patients reacted strongly with both intact
puried PGL-I and the
deacylated form derived from alkaline hydrolysis,
46
whereas healthy control sera or serum
from individuals infected with M. tuberculosis or other atypical
mycobacterial infections
were uniformly negative. Reactivity to a structurally closely
related triglycosylphenolic
diacylphthiocerol puried from M. kansasii (mycoside A), the
monoglycosylphenolic
diacylphthiocerol puried from M. bovis BCG (mycoside B), and a
panel of glyco-
peptidolipids (GPLs) isolated from different members of the M.
avium-M. intracellulare-M.
scrofulaceum (MAIS) complex that contain short type-specic
tetra- or trisaccharide
antigenic determinants were not cross-reactive with the rabbit
or leprosy patient sera.
5
The dissected puried components of PGL-I, including the phenolic
phthiocerol core, the
mycocerosic acids, and deglycosylated PGL-I also showed no
reactivity, indicating that the
reactive component resided within the trisaccharide moiety.
Syntheses of the trisaccharide,
26,
27
the terminal disaccharide,
2629
and a number of incompletely O-methylated analogs were
H
3
C
O
H
3
C
H
3
CO
H
3
CO
H
3
CO
OCH
3
H
3
CO
HO
HO
OH
CH
3
(CH
2
)
18
O
O
O
O
O
O
O
O
O
O
Figure 1. Structure of PGL-I showing C32 mycocerosic acid; C30
and C34 are also found (gure courtesy of
Dr. Michael McNeil at Colorado State University).
J. S. Spencer and P. J. Brennan348
-
used in inhibition assays to eventually show that all of the
exquisite specicity and
recognition by leprosy patient anti-PGL-I polyclonal IgM
antibodies and mouse monoclonal
antibodies
30
were directed against the terminal disaccharide, mainly towards
the nonreducing
3,6-di-O-methyl-b-D-glucopyranosyl moiety, with a specic
requirement for both the 3- and
6-O-methyl substituents. These studies demonstrated that the
trisaccharide structure is unique
and specic forM. leprae PGL-I, the reason for its utility as a
reagent to assist in the diagnosis
of leprosy or categorising patients based on anti-PGL-I titer to
make better decisions on
treatment regimens.
DETECTION OF PGL- I ANTIGEN IN SERUM FROM LEPROSY PATIENTS
Soon after the method of purifying PGL-I from infected armadillo
tissues was described,
similar methods showed that PGL-I was extractable from a number
of biological specimens
from leprosy patients, including skin lesions,
31
serum samples
32,33
and urine.
34
Detection of
PGL-I in serum samples was quite simple; drying as little as
100ml of serum onto a lter
paper disc and extracting lipid material with CHCl
3
/CH
3
OH, 2:1 followed by fractionation on
small silicic acid columns. PGL-I antigen extracted from serum
samples was readily
identied by dot-blot ELISA using rabbit polyclonal anti-PGL-I
antiserum or monoclonal
antibody,
35
methods that had greater sensitivity than using TLC or
high-pressure liquid
chromatography. Untreated lepromatous leprosy patients classied
as BL or LL according
to the Ridley-Jopling classication system
36
were positive for serum PGL-I detection at
between 88%
37
and 96%.
38
The levels of PGL-I in the serum correlated with the BI, with
the
highest levels detected in multibacillary (MB) individuals with
diffuse skin inltration and
skin nodules, and polar lepromatous individuals with a BI.50,
concentrations which ranged
from 1 to 32mg of PGL-I per ml. As the BI decreased, the ability
to detect PGL-I in individual
samples was lower, with less than half of those MB patients with
a BI of,31 being positive,
and no detection in TT/BT individuals with a BI of 0. PGL-I
levels did not vary signicantly
with differences in the duration of pre-existing disease, with
the disability index, or in
those patients who experienced Type 2 ENL (erythema nodosum
leprosum) reactions after
beginning MDT.
37
Monitoring the serum levels of PGL-I after initiating multidrug
therapy (MDT) was
proposed as a means to ascertain the efcacy of drug treatment,
since the active synthesis and
release of PGL-I was shown to be a marker of M. leprae viability
when metabolically
maintained in vitro.
39,40
Following the rst administration of MDT, levels of serum
PGL-I
in patients showed a dramatic decline in concentration, likely
reecting the rapid killing of
bacilli and cessation of new PGL-I synthesis. Successful
treatment generally gave rise to
low circulating PGL-I antigen (less than 100 ng/ml) within 12
months of MDT, even in
individuals with the highest BI. Although the BI detected in
skin lesions of patients decreases
relatively slowly at a rate of 0610 per year with effective
chemotherapy, none of the serum
samples obtained from any patient treated for at least 18 months
had measurable levels of
PGL-I antigen.
Despite the initial promise of using PGL-I antigen detection to
monitor successful MDT
treatment of MB leprosy patients, this method was not applicable
for most individuals with
a BI under 30 or for PB patients, and the purication of PGL-I
from serum samples
is somewhat labour intensive. Eventually, this technique fell by
the wayside in favour of
detecting serum antibodies to either PGL-I or other M. leprae
antigens.
Mycobacterium leprae Phenolic Glycolipid I 349
-
DETECTION OF PGL- I ANTIBODY IN SERUM FROM LEPROSY PATIENTS
After the initial purication and characterisation of M. leprae
PGL-I, it was determined that
the most immunogenic portion of the glycolipid resided with the
novel trisaccharide attached
to the phenolic residue. As had been shown earlier with the
blood group antigens and the
type-specic GPLs of the MAIS complex, antisera are readily
raised that can differentiate
subtle structural differences in their oligosaccharide haptens.
It was shown early on that
individuals with a high BI reective of a high bacillary load
almost universally showed a high
titer of IgM antibodies to PGL-I,
41
which were almost exclusively directed against the
terminal disaccharide. The fact that the antibody response to
PGL-I was mainly of the IgM
class indicates the T cell independent nature of the response to
this glycolipid antigen, unlike
the predominant IgG response to the major M. leprae carbohydrate
antigen, lipoarabino-
mannan (LAM).
4244
Attempts to develop serological assays using native PGL-I were
at rst
problematic due to the apolar nature of the puried glycolipid
and its lack of solubility in
aqueous buffers commonly used in immunodiffusion or ELISA
assays. This issue of
solubility was overcome initially by incorporating native PGL-I
into liposomes, which could
then be shown to form a reactive precipitate by Ouchterlony gel
immunodiffusion.
4
Young and Buchanan
6
partially solved the problem by deacylation of PGL-I, i.e.
removal of
the mycocerosic acids with alkali. Sonication of native PGL-I in
phosphate buffered saline
containing 1mg/ml of the detergent sodium deoxycholate enabled
the antigen to be
efciently coated onto microtiter plate wells in a PGL-I ELISA
assay that reacted with
leprosy patient sera.
45
It was later determined that the use of the detergent Tween,
commonly
used in buffers in ELISA assays, was problematic, as the
detergent interacted with the lipid
portion of the molecule and caused its detachment from the
plastic of the ELISA plate wells.
This problem was alleviated by avoiding the use of detergents in
all blocking and wash
buffers, and by increasing the concentration of bovine serum
albumin to 3% in all buffers
used throughout the procedure. In addition, it was determined
that PGL-I solubilised in 100%
ethanol and dried overnight onto ELISA plate wells was rmly
immobilised onto the plastic;
this is now an aspect of the routine procedure. Using this
detergent-free protocol, ELISA
assays were developed using polyclonal or monoclonal reagents
that were shown to be highly
specic to the sugar entities of PGL-I, and amenable to the
detection of the anti-PGL-I titer in
leprosy patients or household contacts. This development
provided the ability for the rst
time to perform routine screens of populations in high
prevalence areas to gain knowledge of
the clinical and epidemiological signicance of detectable
antibody titer to this antigen,
which allowed an assessment of the potential risk that this
posed in eventual progression from
infection to disease.
46
DEVELOPMENT OF SYNTHETIC PGL-I NEOGLYCOCONJUGATES
Upon denition of the trisaccharide structure of PGL-I, a number
of laboratories developed
synthetic strategies for the production of the terminal
monosaccharide and disaccharide
haptens or the entire trisaccharide to allow for chemical
coupling to water soluble carrier
molecules such as bovine or human serum albumin (BSA, HSA); such
polyvalent structures
had the advantage of multiple hapten substitutions (up to 40) on
each polypeptide backbone,
and, being water soluble, were amenable to the development of
assays more facile than
conventional ELISA. The rst of these neoantigens
e-N-1-[1-deoxy-2,3-di-O-methyl-4-O-
(3,6-di-O-methyl-b-D-glucopyranosyl)rhamnitol]-lysyl-BSA -
essentially a coupling of
J. S. Spencer and P. J. Brennan350
-
the synthetic terminal disaccharide to the lysine residues in
the BSA backbone by reductive
amination, proved highly sensitive in ELISA and showed good
concordance with the
native glycolipid in analysis of serum samples from leprosy
patients.
47
A second generation
of products, one of which is still being generated by the
Colorado group and named
ND-O-BSA/HSA (natural disaccharide-octyl-BSA or -HSA), involved
synthesis of
the terminal monosaccharide, disaccharide and indeed the entire
trisaccharide but as the
8-methoxy-carbonyloctyl sugar(s)
4850
in order to provide a linker arm, which, by using
the strategy of Lemieux et al.
51
allowed attachment to the e-amino groups of the lysines on
the polypeptide backbone, and provided distance between the
reactive hapten and the
polypeptide. Another generation of products pioneered by
Fujiwara,
52,53
chose methyl
3( p-hydroxyphenyl) propionate as the linker arm, since, in the
native PGL-I, the
p-hydroxylphenyl group may contribute to the requirements for
evocation of and binding to
anti-glycolipid antibodies. Indeed, Fujiwara still produces for
the research community the
trisaccharide segment of PGL-I in the form of the
p-(2-methoxycarbonylethyl)phenyl
glycoside coupled to BSA by the acyl azide method, which he
terms NT-P-BSA (natural
trisaccharide-propyl-BSA). Gigg et al.
28
had previously produced the terminal disaccharide
carrying the allyl linker arm and Brett et al.
45
described the coupling of such a disaccharide to
BSA generating the glycoconjugate with the propyl group.
Comparative serological testing in
ELISA of NT-O-BSA, ND-O-BSA and NT-P-BSA against sera from
leprosy patients and
control populations showed concordance; the presence of the
innermost sugar or the phenyl
group apparently did not contribute signicantly to sensitivity
or specicity.
50
USE OF SYNTHETIC GLYCOCONJUGATES IN TESTS TO ASSESS PGL- I
ANTIBODY
IN LEPROSY ENDEMIC AREAS
With the development of these di- and trisaccharide synthetic
neoglycoconjugates, there
followed a number of assay formats and devices amenable to the
testing of individuals at risk
in leprosy endemic areas. The simplest of these is a lateral ow
device that contains a
nitrocellulose detection strip that has two 1mm wide lines
deposited in parallel, one with the
neoglycoconjugate to detect human IgM antibodies to PGL-I (the
test line, T), and the other
containing human IgM as a positive control line (C). The
nitrocellulose strip is anked by a
reagent pad that can receive a serum or whole blood sample with
diluent, which is wicked
towards the nitrocellulose by an absorbent pad at the opposite
end. The nitrocellulose
detection strip and anking pads are encased in a plastic support
with a sample application
port and an open rectangular viewing area over the test and
control lines. As the sample
travels towards the nitrocellulose, it picks up a colloidal
gold-labeled anti-human IgM reagent
that specically binds to human IgM antibody and gives a positive
reaction to the control
and/or test lines. Samples that contain anti-PGL-I antibodies
will display two visible lines,
one being the positive test line against the neoglycoconjugate
which is semiquantitative,
varying in intensity depending on the anti-PGL-I titer (Figure
2); those without any detectable
antibodies develop a single positive control line.
The results are rapid, being easily read in about 10 minutes,
and can be interpreted by
individuals with minimal training, all of which are well-suited
for eld use in resource limited
settings. In an evaluation of one type of anti-PGL-I lateral ow
device, the ML Flow test,
there was agreement in detecting a positive test between a
standard ELISA assay and the ML
Flow 91% of the time, with the ability to detect a positive
reaction in 974% of MB leprosy
patients, 40% of PB patients, and 286% of household
contacts.
54
The specicity of this test
Mycobacterium leprae Phenolic Glycolipid I 351
-
was 902%, which was very good considering that the controls
included a sizable number of
healthy individuals and those with other skin diseases,
including Buruli ulcer, from three
different endemic countries. It was found that these tests were
useful in the correct
classication of MB versus PB individuals after diagnosis,
55
as in general, those with high
levels of anti-PGL-I antibody had a correspondingly high
bacillary load, while those lacking
antibodies were likely to have a negative BI.
56
Other simple tests that preceded the development of the lateral
ow test include a simple
dipstick and a particle agglutination test. The ML Dipstick was
developed as a simple format
that could assist in the classication of conrmed leprosy
patients under eld conditions.
57,58
The dipstick was coated with two bands, one containing ND-O-BSA
and the other a control
anti-human IgM. It was incubated with whole blood or serum mixed
with diluent containing
the detection reagent, anti-human IgM coupled to colloidal gold,
with reactivity to the
ND-O-BSA band indicating a positive reaction. The dipsticks and
reagents were shown to be
stable under tropical eld conditions of heat and humidity,
positives could be easily
distinguished by minimally trained staff, and the concordance,
sensitivity and specicity of
the dipstick with the ELISA assay showed consistently high
agreement at various cutoff
values. Another simple test, the gelatin particle agglutination
test, was developed by
activating gelatin particles with tannic acid, followed by
mixing with NT-P-BSA.
59
Sensitised particles mixed with serial two-fold dilutions of
serum in U-shaped wells were
observed for end point agglutination, which could easily be
discerned by visual examination,
with cut-offs for positivity generally being between 1:64 and
1:128 serum dilutions.
The sensitised particles could be lyophilized for stable
long-term storage and reconstituted
for use. The concordance rates between particle agglutination
and the indirect ELISA assay
was generally .90% in all groups tested, including leprosy
patients and their contacts,
Figure 2. Lateral ow device to detect anti-PGL-I antibody
reactivity in leprosy patient serum samples. C, control
line; T, test line. Positive reactive serum shown on the left
with a strong band at the T line; negative pattern on the
device on the right. Courtesy of Dr. Sang-Nae Cho, Yonsei
University College of Medicine, Seoul, Korea.
J. S. Spencer and P. J. Brennan352
-
TB patients and healthy controls. Thus, these tests have been
reliably used to categorise
those already diagnosed with leprosy for the purposes of dening
treatment regimens and
identifying those contacts of index cases most at risk of
developing this disease based on
a positive anti-PGL-I test.
ROLE OF PGL- I IN THE INFECTIVITY OF SCHWANN CELLS AND THE
IMMUNE
RESPONSE
M. leprae displays a characteristic tropism for peripheral
nerves, and as a result of Schwann
cell (SC) invasion, initiates a process that eventually destroys
the functional integrity of
the nerve, which is the leading cause of neuropathy, disgurement
and disability in
individuals with leprosy. Myelinated and non-myelinated nerves
have associated SC-axon
units that are surrounded by a basal lamina, and a number of
mechanisms have been
proposed for how M. leprae binds to and enters the SC.
60
PGL-I has been shown to bind
specically to laminins, which are glycoproteins that are
involved in the assembly of the
basement membrane in the basal lamina. The specic interaction of
PGL-I with laminin was
shown by binding assays to be directed towards the laminin-2
domain, while there was no
binding to other human matrix proteins, such as collagen,
bronectin, or heparan sulfate
proteoglycan.
61
Removal of the trisaccharide portion of PGL-I, but not removal
of the long-
chain mycocerosic acid residues, abrogated the ability of PGL-I
to bind to laminin-2,
suggesting that the unique sugar residues are the reason for
nerve tropism. Once the SCs have
been invaded, they seem to lack the ability to kill
intracellular bacilli, and large numbers
of bacteria proliferate within these cells and macrophages
within the peripheral nerves.
M. leprae appears to be able to perturb the lipid homeostasis of
infected cells resulting in the
formation of cytoplasmic organelles known as lipid bodies
(LB),
62
which are primarily
responsible for the appearance of foamy macrophages in lesion
sites found in lepromatous
leprosy but not tuberculoid lesions, rst described by Virchow in
1863.
63
The lipids in these
vesicles are mainly host-derived, but their formation is an
active process that requires viable
bacilli. Recent studies showed that M. leprae-induced LB
biogenesis correlated with
increased prostaglandin E
2
(PGE
2
, a potent immune modulator shown to downregulate Th1
responses and bactericidal activity towards intracellular
pathogens) and IL10 and decreased
IL-12 and nitric oxide production in infected SCs,
64
conditions that would favour survival
of the bacteria. Inhibition of biogenesis by a fatty acid
synthase inhibitor abolished this effect
and enhanced the ability of SCs to kill intracellular bacilli.
It appears that LB formation
creates intracellular conditions favourable to the survival and
replication of M. leprae.
The bacilli likely use these LBs as a nutritional source, and
accumulation of LBs in infected
SCs generates an innate immune response that allows for
permissive growth of the bacilli
within the nerve. PGL-I has been shown to play an important role
in downregulating the
inammatory immune response, inhibits dendritic cell maturation
and activation, facilitates
entry of bacilli into macrophages and SCs, and scavenges
potentially cytocidal oxygen
metabolites in vitro, all of which would promote the survival of
intracellular bacilli.
6569
The role of PGL-I is likely crucial to the ability of M. leprae
to invade, survive and
proliferate in the hostile intracellular environment.
Mycobacterium leprae Phenolic Glycolipid I 353
-
THE FUTURE OF PGL-I IN THE SERODIAGNOSIS AND IMMUNOPATHOGENESIS
OF
LEPROSY
Although individuals who test positive for anti-PGL-I antibodies
have about an 8-fold higher
risk to develop leprosy,
70
screening for PGL-I antibodies in the general population is
not
useful, because not every person who develops a positive
anti-PGL-I titer will progress to a
diseased state,
71
and the vast majority of active or potential PB cases are
negative for PGL-I
antibody. Nevertheless, an assessment of anti-PGL-I antibody
titer among contacts would aid
in the identication of those positive individuals who may be
most at risk of developing
the disease, which would allow for better follow-up and reduce
the level of transmission.
In addition, the test is valid to classify newly diagnosed
leprosy patients for the purpose of
providing the correct treatment regimen. In combination with
PGL-I, specic reactivity
against M. leprae recombinant protein antigens ML0405 and
ML2331, which have been
engineered into a fusion protein called LID-1, has shown promise
in the development of a
tool for the assessment of treatment efcacy and disease
relapse,
72
and may be more
effective at the PB end of the disease spectrum. Despite the
limited availability of rapid tests
due to the lack of interest from industry, a number of
governmental health organisations
within countries where leprosy prevalence is high have expressed
an interest in providing
resources for the development and use of these tests for
screening those found to be at risk
for coming down with leprosy. Regardless, serology as such will
always have limited
application in the diagnosis of early leprosy on account of the
requirement of measurable
quantities of antibodies, themselves synonymous with lepromatous
leprosy, otherwise
readily amenable to diagnosis. Attention nowadays has turned
towards diagnostics based on
T-cell responses to novel M. leprae antigens,
73
with the potential to detect the earliest
evidence of M. leprae infection. An equally pressing but more
intractable question, the role
of the copious phthiocerol-based lipids in the particular
immunopathogenesis of leprosy may
have received a boost from recent developments. Arising from
knowledge of the genome
sequence of several isolates/strains of M. leprae, the
underlying genetics and enzymology
of PDIM and PGL-I biosynthesis is now understood.
74,75
Consequently Mycobacterium
bovis BCG has now been engineered to express PGL-I
68
such that questions on the specic
role of PGL-I, anchored on a living mycobacterium, in disease
onset and progression, can
be now addressed.
Acknowledgements
Support from the National Institute of Allergy and Infectious
Diseases/NIH through contract
N01-AI-25469 and grant R37-AI-18357 over a 30 year period. More
recently, the IDEAL
(Initiative for Diagnostic and Epidemiological Assays for
Leprosy) Consortium has supported
our research on leprosy diagnostics.
References
1
Kirchheimer WF, Storrs EE. Attempts to establish the armadillo
(Dasypus novemcinctus Linn.) as a model for the
study of leprosy. I. Report of lepromatoid leprosy in an
experimentally infected armadillo. Int J Lepr, 1971; 39:
693702.
J. S. Spencer and P. J. Brennan354
-
2Brennan PJ, BarrowWW. Evidence for species-specic lipid
antigens inMycobacterium leprae. Int J Lepr, 1980;
48: 382387.
3
Hunter SW, Brennan PJ. A novel phenolic glycolipid from
Mycobacterium leprae possibly involved in
immunogenicity and pathogenicity. J Bacteriol, 1981; 147:
728735.
4
Payne SN, Draper P, Rees RJW. Serological activity of puried
glycolipid fromMycobacterium leprae. Int J Lepr,
1982; 50: 220221.
5
Cho S-N, Yanagihara DL, Hunter SW et al. Serological specicity
of phenolic glycolipid I from Mycobacterium
leprae and use in serodiagnosis of leprosy. Infect Immun, 1983;
41: 10771083.
6
Young DB, Buchanan TM. A serological test for leprosy with a
glycolipid specic for Mycobacterium leprae.
Science, 1983; 221: 10571059.
7
Aspinall GO, Chatterjee D, Brennan PJ. The variable surface
glycolipids of mycobacteria: Structures, synthesis of
epitopes, and biological properties. In: Horton D (ed). Advances
in Carbohydrate Chemistry and Biochemistry.
Academic Press, San Diego, CA, 1995; pp. 169242.
8
Brennan PJ, Goren MB. Structural studies on the type-specic
antigens and lipids of the Mycobacterium avium-
Mycobacterium intracellulare-Mycobacterium scrofulaceum
serocomplex. J Biol Chem, 1979; 254: 42054211.
9
Brennan PJ, Aspinall GO, Nam Shin JE. Structure of the specic
oligosaccharides from the glycopeptidolipid
antigens of serovars in the Mycobacterium avium-Mycobacterium
intracellulare-Mycobacterium scrofulaceum
serocomplex. J Biol Chem, 1981; 256: 68176822.
10
Hunter SW, Murphy RC, Clay K et al. Trehalose-containing
lipooligosaccharides. J Biol Chem, 1983; 258:
1048110487.
11
Chatterjee D, Bozic CM, Knisley C et al. Phenolic glycolipids of
Mycobacterium bovis: new structures and
synthesis of a corresponding seroreactive neoglycoprotein.
Infect Immun, 1989; 57: 322330.
12
Daffe
M, Lacave C, Laneelle M-A, Laneelle G. Structure of the major
triglycosyl phenol-phthiocerol of
Mycobacterium tuberculosis (strain Canetti). Eur J Biochem,
1987; 167: 144160.
13
Daffe
M, Cho S-N, Chatterjee D, Brennan PJ. Chemical synthesis and
seroreactivity of a neoantigen containing
the oligosaccharide hapten of the Mycobacterium
tuberculosis-specic phenolic glycolipid. J Inf Dis, 1991; 163:
161168.
14
Fournie J-J, Riviere M, Puzo G. Structural elucidation of the
major phenolic glycolipid from Mycobacterium
kansasii. I. Evidence for tetrasaccharide structure of the
oligosaccharide moiety. J Biol Chem, 1987; 262:
31743179.
15
Caldwell HD, Kirchheimer WF, Buchanan TM. Identication of a
Mycobacterium leprae specic protein
antigen(s) and its possible application for the serodiagnosis of
leprosy. Int J Lepr, 1979; 47: 477483.
16
Draper P. Protocol 1/79: Purication ofM. leprae. Annex 1 to the
Report of the Enlarged Steering Committee for
Research on the Immunology of Leprosy (IMMLEP) Meeting of 78
February. World Health Organization,
Geneva, 1979; p. 4.
17
Crowle AJ. Immunodiffusion. 2nd edn., Academic Press, New York,
1973; pp. 247303.
18
Hunter SW, Stewart C, Brennan PJ. Purication of phenolic
glycolipid from armadillo and human sources.
Int J Lepr, 1985; 53: 484486.
19
Young DB. Detection of mycobacterial lipids in skin biopsies
from leprosy patients. Int J Lepr, 1981; 49:
198204.
20
Dische Z, Shettles LB. A specic color reaction of methylpentoses
and a spectrophotometric micromethod for
their determination. J Biol Chem, 1948; 175: 595603.
21
Vemuri N, Khandke L, Mahadevan PR et al. Isolation of phenolic
glycolipid I from human lepromatous nodules.
Int J Lepr, 1985; 53: 487489.
22
Izumi S, Sugiyama K, Fujiwara T, et al. Isolation of the
Mycobacterium leprae-specic glycolipid antigen,
phenolic glycolipid-I, from formalin-xed human lepromatous
liver. J Clin Microbiol, 1985; 22: 680682.
23
Gaylord H, Brennan PJ. Leprosy and the leprosy bacillus: recent
developments in characterization of antigens and
the immunology of the disease. Ann Rev Microbiol, 1987; 41:
645675.
24
Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity of
the major specic glycolipid antigen of
Mycobacterium leprae. J Biol Chem, 1982; 257: 1507215078.
25
Hunter SW, Brennan PJ. Further specic extracellular phenolic
glycolipid antigens and a related diacylphthiocerol
from Mycobacterium leprae. J Biol Chem, 1983; 258: 75567562.
26
Fujiwara T, Hunter SW, Cho S-N et al. Chemical synthesis and
serology of disaccharides and trisaccharides
of phenolic glycolipid antigens from the leprosy bacillus and
preparation of a disaccharide protein conjugate
for serodiagnosis of leprosy. Infect Immun, 1984; 43:
245252.
27
Fujiwara T, Aspinall GO, Hunter SW, Brennan PJ. Chemical
synthesis of the trisaccharide unit of the species-
specic phenolic glycolipid from Mycobacterium leprae.
Carbohydrate Res, 1987; 163: 4152.
28
Gigg R, Payne S, Conant R. The allyl group for protection in
carbohydrate-chemistry. 14. Synthesis of 2,3-di-O-
methyl-4-O-(3,6,-di-O-methyl-b-D-glycopyranosyl)-L-rhamnopyranose
(and its a-propyl glycoside) a haptenic
portion of the major glycolipid from Mycobacterium leprae. J
Carbohydr Chem, 1983; 2: 207223.
29
Fujiwara T, Hunter SW, Brennan PJ. Chemical synthesis of
disaccharides of the specic phenolic glycolipid
antigens from Mycobacterium leprae and of related sugars.
Carbohydr Res, 1986; 148: 287298.
Mycobacterium leprae Phenolic Glycolipid I 355
-
30
Young DB, Khanolkar SR, Barg LL, Buchanan TM. Generation and
characterization of monoclonal antibodies
to the phenolic glycolipid of Mycobacterium leprae. Infect
Immun, 1984; 43: 183188.
31
Venkatesan K, Singh HS, Bhardwaj VP, Ramu G. Isolation,
purication and quantication of phenolic glycolipid-
1 from human leprosy skin tissues. Trans R Soc Trop Med Hyg,
1985; 82: 321323.
32
Young DB, Harnisch JP, Knight J, Buchanan TM. Detection of
phenolic glycolipid I in sera from patients with
lepromatous leprosy. J Infect Dis, 1985; 152: 10781081.
33
Cho S-N, Hunter SW, Gelber RH et al. Quantitation of the
phenolic glycolipid of Mycobacterium leprae and
relevance to glycolipid antigenemia in leprosy. J Infect Dis,
1986; 153: 560569.
34
Kaldany RR, Maasho K, Ohman R et al. Methods of detection of a
specic Mycobacterium leprae antigen in
the urine of leprosy patients. Scand J Immunol, 1987; 25:
3743.
35
Cho S-N, Shin J-S, Daffe
M et al. Production of monoclonal antibody to phenolic
glycolipid of Mycobacterium
tuberculosis and its use in detection of the antigen in clinical
isolates. J Clin Microbiol, 1992; 30: 30653069.
36
Ridley DS, Jopling WH. Classication of leprosy according to
immunity. A ve group system. Int J Lepr, 1966;
34: 255273.
37
Cho S-N, Cellona RV, Fajardo TT et al. Detection of phenolic
glycolipid-I antigen and antibody in sera from
new and relapsed lepromatous patients treated with various drug
regimens. Int J Lepr, 1991; 59: 2531.
38
Roche PW, Britton WJ, Neupane KD et al. The response to
chemotherapy of serum Mycobacterium leprae-
specic antigen in multibacillary leprosy patients. Am J Trop Med
Hyg, 1991; 44: 702708.
39
Franzblau SG, Harris EB, Hastings RC. Axenic incorporation of
[
14
C] palmitic acid into the phenolic glycolipid-I
of Mycobacterium leprae. FEMS Microbiol Lett, 1989; 48:
407411.
40
Mistry Y, Antia NH, Mukherjee R. Correlation of bacterial
viability with uptake of [
14
C] acetate into phenolic
glycolipid-1 of Mycobacterium leprae within Schwannoma cells. J
Biosci, 1989; 14: 3745.
41
Young DB, Dissanayake S, Miller RA et al. Humans respond
predominantly with IgM immunoglobulin to the
species-specic glycolipid of Mycobacterium leprae. J Inf Dis,
1984; 149: 870873.
42
Hunter SW, Gaylord H, Brennan PJ. Structure and antigenicity of
the phosphorylated antigens from the leprosy
and tubercle bacilli. J Biol Chem, 1986; 261: 1234512351.
43
Gaylord H, Brennan PJ, Young DB, Buchanan TM. MostMycobacterium
leprae carbohydrate-reactive antibodies
are directed to lipoarabinomannan. Infect Immun, 1987; 55:
28602863.
44
Sousa AO, Henry S, Maro
ja FM et al. IgG subclass distribution of antibody responses to
protein and
polysaccharide mycobacterial antigens in leprosy and
tuberculosis patients. Clin Exp Immunol, 1998; 111: 4855.
45
Brett SJ, Draper P, Payne SN, Rees RJW. Serological activity of
a characteristic phenolic glycolipid from
Mycobacterium leprae in sera from patients with leprosy and
tuberculosis. Clin Exp Immunol, 1983; 52: 271279.
46
Douglas JT, Cellona RV, Fajardo TT et al. Prospective study of
serological conversion as a risk factor for
development of leprosy among household contacts. Clin Diagn Lab
Immunol, 2004; 11: 897900.
47
Cho S-N, Fujiwara T, Hunter SW et al. Use of an articial antigen
containing the 3,6-di-O-methyl-
b-D-glycopyranosyl epitope for the serodiagnosis of leprosy. J
Infect Dis, 1984; 150: 311322.
48
Chatterjee D, Douglas JT, Cho S-N et al. Synthesis of
neoglycoproteins containing the 3,6-di-O-methyl-
b-D-glucopyranosyl epitope and their use in serodiagnosis of
leprosy. Glycoconjugate J, 1985; 2: 187208.
49
Chatterjee D, Cho S-N, Brennan PJ. Chemical synthesis and
seroreactivity of O-(3,6-di-O-methyl-
b-D-glucopyranosyl)-(1!
4)-O(2,3-di-O-methyl-a-L-rhamnopyranosyl)-(1! 9)-oxynonanoyl-bovine
serum
albumin The leprosy-specic, natural
disaccharide-octyl-neoglycoprotein. Carbohydr Res, 1986; 156:
3956.
50
Chatterjee D, Cho S-N, Stewart C et al. Synthesis and
immunoreactivity of neoglycoproteins containing the
trisaccharide unit of phenolic glycolipid I of Mycobacterium
leprae. Carbohydr Res, 1988; 183: 241260.
51
Lemieux RU, Baker DA, Bundle DR. A methodology for the
production of carbohydrate-specic antibody.
Can J Biochem, 1977; 55: 507512.
52
Fujiwara T, Izumi S, Brennan PJ. Synthesis of
3,6-di-O-methylglucosyl disaccharides with methyl
3-(p-hydroxyphenyl)propionate as a linker and their use in the
serodiagnosis of leprosy. Agric Biol Chem,
1985; 49: 23012308.
53
Fujiwara T, Izumi S. Synthesis of the neoglycoconjugates of
phenolic glycolipid-related trisaccharides for the
serodiagnosis of leprosy. Agric Biol Chem, 1987; 51:
25392547.
54
Bu
hrer-Se
kula S, Smits HL, Gussenhoven GC et al. Simple and fast lateral
ow test for classication of leprosy
patients and identication of contacts with high risk of
developing leprosy. J Clin Microbiol, 2003; 41:
19911995.
55
Buhrer-Se
kula S, Sarno EN, Oskam L et al. Use of ML dipstick as a tool to
classify leprosy patients. Int J Lepr,
2000; 68: 456463.
56
Klatser PR, Cho SN, Brennan PJ. The contribution of serological
tests to leprosy control. Int J Lepr, 1996; 64:
S63S66.
57
Buhrer-Se
kula S, Cunha MGS, Ferreira WA, Klatser PR. The use of whole
blood in a dipstick assay for detection
of antibodies to Mycobacterium leprae: a eld evaluation. FEMS
Immunol Med Microbiol, 1998; 21: 197201.
58
Bu
hrer-Se
kula S, Cunha MG, Foss NT et al.Dipstick assay to identify
leprosy patients who have an increased risk
of relapse. Trop Med Int Health, 2001; 6: 317323.
J. S. Spencer and P. J. Brennan356
-
59
Izumi S, Fujiwara T, Ikeda M et al. Novel gelatin particle
agglutination test for serodiagnosis of leprosy in the
eld. J Clin Microbiol, 1990; 28: 525529.
60
Scollard DM, Adams LB, Gillis TP et al. The continuing
challenges of leprosy. Clin Microbiol Rev, 2006; 19:
338381.
61
Ng V, Zanazzi G, Timpl R et al. Role of the cell wall phenolic
glycolipid-1 in the peripheral nerve predilection of
Mycobacterium leprae. Cell, 2000; 103: 511524.
62
Mattos KA, DAvila H, Rodrigues LS et al. Lipid droplet formation
in leprosy: Toll-like receptor-regulated
organelles involved in eicosanoid formation andMycobacterium
leprae pathogenesis. J Leukocyte Biol, 2010; 87:
371384.
63
Virchow R. Die krankhaften Geschwu
lste. August Hirschwald, Berlin, 1863.
64
Mattos KA, Oliveira VG, DAvila H et al. TLR6-driven lipid
droplets inMycobacterium leprae-infected Schwann
cells: Immunoinammatory platforms associated with bacterial
persistence. J Immunol, 2011; In press.
65
Schlesinger LS, Horwitz MA. Phenolic glycolipid-I of
Mycobacterium leprae binds complement component C3
in serum and mediates phagocytosis by human monocytes. J Exp
Med, 1991; 174: 10311038.
66
Murray RA, Siddiqui MR, Mendillo M et al. Mycobacterium leprae
inhibits dendritic cell activation and
maturation. J Immunol, 2007; 178: 338344.
67
Sinsimer D, Fallows D, Peixoto B et al. Mycobacterium leprae
actively modulates the cytokine response in na
ve
human monocytes. Infect Immun, 2010; 78: 293300.
68
Tabouret G, Astarie-Dequeker C, Demangel C et al. Mycobacterium
leprae phenolglycolipid-1 expressed by
engineeredM. bovis BCG modulates early interaction with human
phagocytes. PLoS Pathog, 2010; 6: e1001159.
69
Chan J, Fujiwara T, Brennan PJ et al. Microbial glycolipids:
possible virulence factors that scavenge oxygen
radicals. Proc Natl Acad Sci, 1989; 86: 24532457.
70
Van Beers SM, Hatta M, Klatser PR. Patient contact is the major
determinant in incident leprosy: implications
for future control. Int J Lepr, 1999; 67: 119128.
71
Cunaman A, Jr, Chan GP, Douglas JT. Risk of development of
leprosy among Culion contacts. Int J Lepr, 1998;
66: S78A.
72
Duthie MS, Hay MN, Rada EM et al. Specic IgG antibody responses
may be used to monitor leprosy treatment
efcacy and as recurrence prognostic markers. Eur J Clin
Microbiol Inf Dis, 2011; In press.
73
Geluk A, Spencer JS, Bobosha K et al., and on behalf of the
IDEAL Consortium. From genome-based in silico
predictions to ex vivo verication of leprosy diagnosis. Clin
Vaccine Immunol, 2009; 16: 352359.
74
Constant P, Pe
rez E, Malaga W et al. Role of the pks15/1 gene in the
biosyntheisis of phenolglycolipids in the
Mycobacterium tuberculosis complex. Evidence that all strains
synthesize glycosylated p-hydroxybenzoic methyl
esters and that strains devoid of phenolglycolipids harbor a
frameshift mutation in the pks15/1 gene. J Biol Chem,
2002; 277: 3814838158.
75
Pe
rez E, Constant P, Lemassu E et al. Characterization of three
glycosyltransferases involved in the biosynthesis
of the phenolic glycolipid antigens from the Mycobacterium
tuberculosis complex. J Biol Chem, 2004; 279:
4257442583.
Mycobacterium leprae Phenolic Glycolipid I 357